How past pregnancies affect gynecologic cancer treatment
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at whether having been pregnant in the past influences how well immunotherapy (PD-1/PD-L1 inhibitors) works for endometrial or cervical cancer. The goal is to see if pregnancy history might be linked to better or worse outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who is 18 or older.
- You have been diagnosed with endometrial or cervical cancer (confirmed by a biopsy).
- You are being treated with an immunotherapy drug (PD-1 or PD-L1 inhibitor) alone or with chemotherapy.
- If you have ever been pregnant, your obstetric history (details of past pregnancies) must be available.
- You must be able to give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows young women (ages 15–39) diagnosed with cancer from 2025 onward to understand how cancer treatments affect their ability to have children and their pregnancy health. Researchers will track fertility preservation (ways to protect eggs or ovarian function) and pregnancies over time.
This study looks at how well immunotherapy works for advanced endometrial and cervical cancer by checking certain markers in your blood and tumor. It aims to find out which patients benefit most from this treatment.
This study looks at pregnant people who were diagnosed with cancer around pregnancy and how care affects the mother, baby, and newborn. It aims to better understand outcomes and treatment patterns during pregnancy.
This study looks at how immune checkpoint inhibitors (a type of immunotherapy) affect the gut microbiome and ovarian function in women with cancer. It may help understand why some women have different fertility outcomes after treatment.
This study looks at how a newer cancer treatment (immunotherapy combined with hormone injections) affects ovarian health and fertility in young women with triple-negative breast cancer. It may help doctors better protect fertility during cancer treatment.
This trial looks at how a blood inflammation marker (CRP) changes when people with metastatic gynecologic cancers receive immunotherapy, sometimes together with palliative chemotherapy. The goal is to see patterns that may help doctors better understand and manage treatment responses to immunotherapy.
Hear when a new Gynecologic Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.